News & Updates

Show Multimedia Only

Psoriasis control maintained with less frequent guselkumab dosing

11 Aug 2024 by

A 16-week dosing interval for the IL-23 inhibitor guselkumab appears to sufficiently keep psoriasis controlled among patients who have achieved complete skin clearance shortly after starting standard treatment with the drug, according to the phase IIIb GUIDE clinical trial.

Psoriasis control maintained with less frequent guselkumab dosing

11 Aug 2024

Original New Drug Application Approvals by US FDA (16-31 July 2024)

06 Aug 2024

New drug applications approved by US FDA as of 16-31 July 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2024)

06 Aug 2024

Lebrikizumab matches up to dupilumab for atopic dermatitis in adults

01 Aug 2024

Lebrikizumab and dupilumab appear to be equally efficacious when used in the short-term treatment of atopic dermatitis in adults, according to the results of a network meta-analysis.

Lebrikizumab matches up to dupilumab for atopic dermatitis in adults

01 Aug 2024

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

In the treatment of patients with anogenital lichen sclerosus, the use of hydroxychloroquine appears to induce favourable response rates with low incidence of adverse effects, as shown in a retrospective study.

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

31 Jul 2024

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

29 Jul 2024

The use of oral corticosteroids for more than 90 days among individuals with atopic dermatitis (AD) appears to be associated with a slight increase in the risk of adverse events (AEs), according to a study.

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

29 Jul 2024

Investigational IL-13 inhibitor shows therapeutic potential in atopic dermatitis

24 Jul 2024

The IL-13 inhibitor cendakimab appears to be beneficial in the treatment of atopic dermatitis (AD), with the results of a phase II study showing that a dosing schedule of 720 mg once weekly helps reduce the severity of the said condition.

Investigational IL-13 inhibitor shows therapeutic potential in atopic dermatitis

24 Jul 2024

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

22 Jul 2024 by

Benralizumab offers more sustained and earlier elimination of oral GCs vs mepolizumab in patients with relapsing or refractory EGPA, suggests a post hoc analysis of the MANDARA study presented at EULAR 2024

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

22 Jul 2024

JAK inhibitors for autoimmune disease may confer protection against AMD

20 Jul 2024 by

The use of Janus kinase (JAK) inhibitors in the treatment of major autoimmune diseases appears to reduce the risk of age-related macular degeneration (AMD) for people above 40 years of age, according to a study.

JAK inhibitors for autoimmune disease may confer protection against AMD

20 Jul 2024

Oral roflumilast trims weight in patients with psoriasis

20 Jul 2024 by

Treatment with oral roflumilast results in reduced body weight and appetite after 24 weeks in patients with psoriasis, a study has shown.

Oral roflumilast trims weight in patients with psoriasis

20 Jul 2024

Several cases of classic dermatomyositis progress to postmyopathic DM

19 Jul 2024

Nearly half of patients with classic dermatomyositis (DM) develop into postmyopathic (PM)DM, according to a study. Many of them continue to suffer from muscle disease or have moderate or severe skin disease.

Several cases of classic dermatomyositis progress to postmyopathic DM

19 Jul 2024

News & Updates

Filter by Specialty:

Specialty:

Psoriasis control maintained with less frequent guselkumab dosing

Psoriasis control maintained with less frequent guselkumab dosing

Original New Drug Application Approvals by US FDA (16-31 July 2024)

Original New Drug Application Approvals by US FDA (16-31 July 2024)

Lebrikizumab matches up to dupilumab for atopic dermatitis in adults

Lebrikizumab matches up to dupilumab for atopic dermatitis in adults

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

Hydroxychloroquine a promising treatment option for anogenital lichen sclerosus

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

More than 90 days of oral steroids tied to higher AE risk in atopic dermatitis

Investigational IL-13 inhibitor shows therapeutic potential in atopic dermatitis

Investigational IL-13 inhibitor shows therapeutic potential in atopic dermatitis

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

Benralizumab facilitates complete withdrawal of OGCs more than mepolizumab in EGPA

JAK inhibitors for autoimmune disease may confer protection against AMD

JAK inhibitors for autoimmune disease may confer protection against AMD

Oral roflumilast trims weight in patients with psoriasis

Oral roflumilast trims weight in patients with psoriasis

Several cases of classic dermatomyositis progress to postmyopathic DM

Several cases of classic dermatomyositis progress to postmyopathic DM